Hanmi Pharm. Co., Ltd.

Symbol: 128940.KS

KSC

322000

KRW

Market price today

  • 24.3478

    P/E Ratio

  • 0.0155

    PEG Ratio

  • 4.09T

    MRK Cap

  • 0.00%

    DIV Yield

Hanmi Pharm. Co., Ltd. (128940-KS) Stock Price & Analysis

Shares Outstanding

12.69M

Gross Profit Margin

0.67%

Operating Profit Margin

0.16%

Net Profit Margin

0.11%

Return on Assets

0.09%

Return on Equity

0.18%

Return on Capital Employed

0.19%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Jae-Hyun Park
Full-time employees:2235
City:Seoul
Address:14, Wiryeseong-daero
IPO:2010-07-30
CIK:

Hanmi Pharm. Co., Ltd. operates as a pharmaceutical company worldwide. It develops treatments for diabetes, obesity, cancer, autoimmune, and rare diseases. The company was founded in 1973 and is based in Seoul, South Korea.

General Outlook

In simple terms, Hanmi Pharm. Co., Ltd. has 12.688 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.671% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.158%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.108%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.085% return, is a testament to Hanmi Pharm. Co., Ltd.'s adeptness in optimizing resource deployment. Hanmi Pharm. Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.177%. Furthermore, the proficiency of Hanmi Pharm. Co., Ltd. in capital utilization is underscored by a remarkable 0.194% return on capital employed.

Stock Prices

Hanmi Pharm. Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $334500, while its low point bottomed out at $327000. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Hanmi Pharm. Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 128940.KS liquidity ratios reveals its financial health of the firm. The current ratio of 106.13% gauges short-term asset coverage for liabilities. The quick ratio (61.43%) assesses immediate liquidity, while the cash ratio (7.79%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio106.13%
Quick Ratio61.43%
Cash Ratio7.79%

Profitability Ratios

128940.KS profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 13.93% underscores its earnings before tax deductions. The effective tax rate stands at 16.26%, revealing its tax efficiency. The net income per EBT, 77.83%, and the EBT per EBIT, 88.15%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 15.81%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin13.93%
Effective Tax Rate16.26%
Net Income per EBT77.83%
EBT per EBIT88.15%
EBIT per Revenue15.81%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.06, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding61
Days of Inventory Outstanding209
Operating Cycle251.46
Days of Payables Outstanding33
Cash Conversion Cycle219
Receivables Turnover8.56
Payables Turnover11.17
Inventory Turnover1.75
Fixed Asset Turnover1.78
Asset Turnover0.79

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 17061.84, and free cash flow per share, 13515.62, depict cash generation on a per-share basis. The cash per share value, 20025.92, showcases liquidity position. Lastly, the operating cash flow sales ratio, 0.14, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share17061.84
Free Cash Flow per Share13515.62
Cash per Share20025.92
Operating Cash Flow Sales Ratio0.14
Free Cash Flow to Operating Cash Flow Ratio0.79
Cash Flow Coverage Ratio0.38
Short Term Coverage Ratio0.45
Capital Expenditure Coverage Ratio4.81
Dividend Paid and Capex Coverage Ratio4.75

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 28.99%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.59, we discern the balance between debt and equity financing. The long-term debt to capitalization, 7.91%, and total debt to capitalization, 37.19%, ratios shed light on its capital structure. An interest coverage of 11.44 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio28.99%
Debt Equity Ratio0.59
Long Term Debt to Capitalization7.91%
Total Debt to Capitalization37.19%
Interest Coverage11.44
Cash Flow to Debt Ratio0.38
Company Equity Multiplier2.04

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 117472.82, provides a glimpse into top-line earnings distributed across each share. Net income per share, 11522.12, reflects the portion of profit attributed to each share. The book value per share, 75283.02, represents the net asset value distributed per share, while the tangible book value per share, 80304.01, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share117472.82
Net Income Per Share11522.12
Book Value Per Share75283.02
Tangible Book Value Per Share80304.01
Shareholders Equity Per Share75283.02
Interest Debt Per Share46828.17
Capex Per Share-3762.14

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 11.97%, indicates top-line expansion, while the gross profit growth, 16.32%, reveals profitability trends. EBIT growth, 42.25%, and operating income growth, 42.25%, offer insights into operational profitability progression. The net income growth, 76.63%, showcases bottom-line expansion, and the EPS growth, 76.79%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth11.97%
Gross Profit Growth16.32%
EBIT Growth42.25%
Operating Income Growth42.25%
Net Income Growth76.63%
EPS Growth76.79%
EPS Diluted Growth76.79%
Weighted Average Shares Growth-0.10%
Weighted Average Shares Diluted Growth-0.10%
Dividends per Share Growth200.60%
Operating Cash Flow Growth33.44%
Free Cash Flow Growth49.80%
10-Year Revenue Growth per Share96.64%
5-Year Revenue Growth per Share44.36%
3-Year Revenue Growth per Share39.04%
10-Year Operating CF Growth per Share142.50%
5-Year Operating CF Growth per Share719.87%
3-Year Operating CF Growth per Share43.37%
10-Year Net Income Growth per Share220.54%
5-Year Net Income Growth per Share321.17%
3-Year Net Income Growth per Share748.57%
10-Year Shareholders Equity Growth per Share124.75%
5-Year Shareholders Equity Growth per Share33.66%
3-Year Shareholders Equity Growth per Share31.32%
3-Year Dividend per Share Growth per Share121.80%
Receivables Growth-6.26%
Inventory Growth8.50%
Asset Growth1.43%
Book Value per Share Growth9.69%
Debt Growth-19.88%
R&D Expense Growth24.57%
SGA Expenses Growth79.23%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 5,061,386,662,247, captures the company's total value, considering both debt and equity. Income quality, 1.48, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.04, gauges operational efficiency, while the research and development to revenue, 12.89%, highlights investment in innovation. The ratio of intangibles to total assets, 4.15%, indicates the value of non-physical assets, and capex to operating cash flow, -22.05%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value5,061,386,662,247
Income Quality1.48
Sales General and Administrative to Revenue0.04
Research and Development to Revenue12.89%
Intangibles to Total Assets4.15%
Capex to Operating Cash Flow-22.05%
Capex to Revenue-3.20%
Capex to Depreciation-48.50%
Graham Number139703.08
Return on Tangible Assets7.82%
Graham Net Net-25124.61
Working Capital43,236,633,060
Tangible Asset Value1,019,165,488,635
Net Current Asset Value-103,171,560,270
Invested Capital1
Average Receivables185,179,539,164.5
Average Payables42,444,882,500
Average Inventory277,499,585,099.5
Days Sales Outstanding44
Days Payables Outstanding25
Days of Inventory On Hand161
ROIC12.62%
ROE0.15%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 4.24, and the price to book ratio, 4.24, reflect the market's valuation relative to the company's book value. The price to sales ratio, 2.64, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 23.60, and price to operating cash flows, 18.70, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio4.24
Price to Book Ratio4.24
Price to Sales Ratio2.64
Price Cash Flow Ratio18.70
Price Earnings to Growth Ratio0.02
Enterprise Value Multiple6.36
Price Fair Value4.24
Price to Operating Cash Flow Ratio18.70
Price to Free Cash Flows Ratio23.60
Price to Tangible Book Ratio4.76
Enterprise Value to Sales3.39
Enterprise Value Over EBITDA15.65
EV to Operating Cash Flow23.37
Earnings Yield3.22%
Free Cash Flow Yield3.72%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Hanmi Pharm. Co., Ltd. (128940.KS) on the KSC in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 24.348 in 2024.

What is the ticker symbol of Hanmi Pharm. Co., Ltd. stock?

The ticker symbol of Hanmi Pharm. Co., Ltd. stock is 128940.KS.

What is company IPO date?

IPO date of Hanmi Pharm. Co., Ltd. is 2010-07-30.

What is company current share price?

Current share price is 322000.000 KRW.

What is stock market cap today?

The market cap of stock today is 4085576894000.000.

What is PEG ratio in 2024?

The current 0.015 is 0.015 in 2024.

What is the number of employees in 2024?

In 2024 the company has 2235.